IL1B and hepatocellular carcinoma: The results of this study demonstrate that the PEIM potentiates the anti-HCC effect by reducing inflammation due to down-regulating the expression of TLR4, MyD88, p-NF-κBp65, TNF-α, IL-1β, INOS, IL-6, JAK2, and STAT3, and reducing the content of TNF-α, IL-1β, and IL-6.